🇺🇸 FDA
Patent

US 10689347

Substituted heterocyclyl derivatives as CDK inhibitors

granted A61KA61K31/415A61K31/4155

Quick answer

US patent 10689347 (Substituted heterocyclyl derivatives as CDK inhibitors) held by Aurigene Discovery Technologies Limited expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Aurigene Discovery Technologies Limited
Grant date
Tue Jun 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K31/415, A61K31/4155, A61K31/416, A61K31/4439